logo
Lyssavirus is rare, but deadly — what should you do if bat bites you?

Lyssavirus is rare, but deadly — what should you do if bat bites you?

Indian Express2 days ago
By Vinod Balasubramaniam
A man in his 50s has died from lyssavirus in New South Wales after being bitten by a bat several months ago.
This is Australia's fourth human case of bat lyssavirus and the first confirmed case in NSW since the virus was first identified in 1996 in a black flying fox in Queensland. So what is lyssavirus? And how can you protect yourself if you come into contact with a bat?
Australian bat lyssavirus belongs to the Rhabdoviridae family, the same group of viruses that causes rabies.
It primarily infects bats. Active monitoring suggests fewer than 1 per cent of healthy bats carry the virus, though prevalence rises to 5–10 per cent in sick or injured bats. In bats, the virus often causes no obvious symptoms, though some show neurological signs such as disorientation, aggression, muscle spasms and paralysis. Some will die.
The virus has been confirmed in all four mainland flying fox species (Pteropus alecto, P. poliocephalus, P. scapulatus and P. conspicillatus) as well as the yellow-bellied sheathtail bat (Saccolaimus flaviventris), a species of microbat.
However, serological evidence – where scientists test for antibodies in bats' blood – suggests other microbats could be susceptible too. So we should be cautious with all Australian bat species when it comes to lyssavirus.
Unlike rabies, which causes roughly 59,000 human deaths annually, predominantly in Africa and Asia, human infection with bat lyssavirus is extremely rare. Australian bat lyssavirus, as the name suggests, is unique to Australia. But other bat lyssaviruses, such as European bat lyssavirus, have similarly caused rare human infections.
Human infection with bat lyssavirus occurs through direct contact with infected bat saliva via bites, scratches or open skin. It can also occur if our mucous membranes (eyes, nose, mouth) are exposed to bat saliva. There's no risk associated with bat faeces, urine, blood, or casual proximity to roosts.
If someone has been exposed, there's an incubation period which can range from weeks to more than two years. During this time the virus slowly moves through the body's nerves to the brain, staying hidden and symptom-free.
Treating the virus during the incubation period can prevent the illness. But if it's not treated, symptoms are serious and it's invariably fatal.
The nature of the illness in humans mirrors rabies, beginning with flu-like symptoms (fever, headache, fatigue), then quickly progressing to severe neurological disease, including paralysis, delirium, convulsions, and loss of consciousness. Death generally occurs within 1–2 weeks of symptom onset. All four recorded human cases in Australia – three in Queensland (in 1996, 1998 and 2013) and the recent NSW case – have been fatal.
There's no effective treatment once symptoms develop If someone is potentially exposed to bat lyssavirus and seeks medical attention, they can be treated with post-exposure prophylaxis, consisting of rabies antibodies and the rabies vaccine. This intervention is highly effective if initiated promptly – preferably within 48 hours, and no later than seven days post-exposure – before the virus enters the central nervous system.
But no effective treatment exists for Australian bat lyssavirus once symptoms develop. Emerging research on monoclonal antibodies offers potential future therapies, however these are not yet available.
Pre-exposure rabies vaccination, involving three doses over one month, is recommended for high-risk groups. This includes veterinarians, animal handlers, wildlife rehabilitators, and laboratory workers handling lyssaviruses.
It's important for members of the public to avoid all direct contact with bats. Only vaccinated, trained professionals, such as wildlife carers or veterinarians, should handle bats.
Public education campaigns are essential to reduce risky interactions, especially in bat-populated areas. If you get bitten or scratched by a bat, it's vital to act immediately. Wash the wound thoroughly with soap and water for at least 15 minutes, apply an antiseptic (such as betadine), and seek urgent medical attention.
This tragic case in NSW underscores that while extremely rare, bat lyssavirus is an important public health threat. We need to see enhanced public awareness and ensure vaccination for high-risk groups, alongside ongoing bat monitoring and research into new treatments.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Godavari Biorefineries secures EU patent for anti-cancer molecule
Godavari Biorefineries secures EU patent for anti-cancer molecule

Fibre2Fashion

time2 hours ago

  • Fibre2Fashion

Godavari Biorefineries secures EU patent for anti-cancer molecule

Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB) announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. This milestone underscores the company's growing presence in high-impact scientific innovation, led by its dedicated Anti-Cancer Research Segment. Godavari Biorefineries' anti-cancer molecule patent has been validated in Spain, the UK, and as a Unitary Patent in the EU. Now in Phase 1a trials, the molecule shows promise against various cancers. This milestone boosts GBL's scientific innovation presence, led by Sathgen Therapeutics, and supports its broader push into biotech alongside its core bio-based businesses. The patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells, marking a promising advance toward more targeted and effective cancer therapies. It has shown potential in the treatment of various cancers, including breast and prostate cancer, with encouraging efficacy and safety profiles in preclinical animal studies. The molecule is currently in Phase 1a clinical trials to assess safety in human patients with advanced solid tumors as well as in healthy volunteers. "This patent validation marks a significant milestone in our journey toward advancing original, high-quality scientific research," said Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. "It reflects the dedication of our teams and our aspiration to contribute meaningfully to global knowledge and innovation." Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its investment in translational research that addresses some of the world's most urgent health challenges. This development highlights GBL's growing diversification into advanced scientific domains, complementing its leadership in ethanol, bio-based chemicals, and renewable materials produced from agricultural feedstocks. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. ALCHEMPro News Desk (HU)

Are generic medicines as good as branded ones? Here's what you should know
Are generic medicines as good as branded ones? Here's what you should know

Business Standard

time5 hours ago

  • Business Standard

Are generic medicines as good as branded ones? Here's what you should know

When you pick a generic medicine over a branded one, you're saving money, but how much do you really know about what's in that tablet? PM Modi calls India the 'Pharmacy of the World,' with the pharmaceutical industry valued at around $50 billion in FY24 and expected to grow to $120–130 billion by 2030, according to a December 2024 statement by the Ministry of Chemicals and Fertilisers. Generics drive this growth, contributing 70–80 per cent of India's retail pharma revenue and nearly 100 per cent of volume in some areas. However, the Central Drugs Standard Control Organisation (CDSCO), under India's Ministry of Health and Family Welfare (MoHFW), which serves as the national regulatory authority for ensuring the safety, efficacy, and quality of pharmaceuticals, has raised some red flags. In April 2025, the CDSCO released yet another list of Not of Standard Quality (NSQ) drugs, highlighting persistent concerns about substandard pharmaceuticals in India. What are generic medicines and how are they different from branded ones? A generic medicine is essentially a more affordable version of a branded drug. As Jeevan Kasara, Director and CEO of Steris Healthcare Pvt. Ltd, explained, generics contain the same active ingredient, dosage, strength, and intended use as their branded counterparts. When a pharmaceutical company's patent expires, other companies are allowed to manufacture the same medicine, usually under its chemical name rather than a branded label. Do generics differ in dosage, strength, or effectiveness? Generics are required to match branded medicines in dosage, form, strength, route of administration, and purpose. Minor differences—such as colour, packaging, or inactive ingredients—may exist, but the core active compound remains identical. Are generic medicines as safe and effective in real life? Jeevan Kasara stated that reputable manufacturers follow strict regulatory protocols and conduct bioequivalence studies to demonstrate that generics perform the same as branded versions in the body. CDSCO policies and international audits—such as from the USFDA or European regulators—ensure quality standards, especially for exported generics. Buying from licensed pharmacies and trusted sources is key to safety. Why do people hesitate to trust generic drugs? Dr Jagadish Hiremath, a public health expert, said, 'There's a belief that cheaper means lower quality. But that's not true for CDSCO-approved generics.' Brand familiarity and years of marketing have made some patients wary. In specific cases—like psychiatric, thyroid, or epilepsy medications—doctors may stick with known brands due to sensitivity in absorption rates. But for most common conditions, generics are equally effective. How much money can you save by choosing generics? Generic medicines can be 30 to 90 per cent cheaper than branded ones, according to Kasara. For young professionals without insurance, this can translate into major savings over time—without compromising quality. How can you verify if a generic medicine is trustworthy? Use this quick safety checklist: Buy only from licensed pharmacies Check batch number and expiry date Look for manufacturing and approval details Prefer reputed pharmaceutical manufacturers Apps like Tata 1mg, Netmeds, and Medlife can help verify generic equivalents and manufacturer ratings. Advanced users can consult CDSCO's site or the USFDA Orange Book. Why don't more doctors prescribe generics openly? Dr Hiremath attributes it to both caution and habit. Some doctors are concerned about patients using low-quality products from unverified sources. Others are influenced by pharmaceutical marketing and patient preference for known brands. Are Jan Aushadhi stores helping improve access to generics? Experts agree that Jan Aushadhi outlets offer an affordable route to essential medicines, especially for those managing chronic illnesses. However, Dr Hiremath emphasised that success depends on robust quality checks, public education, consistent supply chains, and accessible databases. Should you choose generic or branded medicines? Here's a quick recap: For most routine treatments, high-quality generics are just as safe and effective For specific, sensitive conditions, consult your doctor before switching Always purchase from trusted pharmacies or platforms Stay informed and ask questions to make safe, economical decisions 'Saving money should never feel risky when it comes to your health,' said Dr Hiremath. 'Stay informed, ask questions, and choose wisely.'

Need for vigilance amid new 'Nimbus' Covid variant
Need for vigilance amid new 'Nimbus' Covid variant

Time of India

time6 hours ago

  • Time of India

Need for vigilance amid new 'Nimbus' Covid variant

Representative image What you need to know NB.1.8.1. — also called "Nimbus' — is a subvariant of the dominant Omicron variant of SARS-CoV-2. It has been detected in South and Southeast Asia and circulating in many EU/EEA countries. It may lead to hospitalizations over the summer. The European centre for disease prevention and control (ECDC) recommends boosters for at-risk groups or those working in high-risk settings. Testing is recommended for people who are sick and have symptoms that worsen. European health authorities are warning there may be an increase in Covid-19 infections in the coming months amid the spread of the new Omicron variant NB.1.8.1. or "Nimbus." "We have what feels like a fairly standard suite of recommendations that are being repeated," Ajibola Omokanye, an ECDC respiratory viruses expert, told DW. "But we remain watchful." The 2024-2025 winter in the Northern Hemisphere has given experts like Omokanye good reason to be watchful. Population immunity against SARS-CoV-2, the virus that causes Covid-19, is down in Europe, probably due to fewer Covid cases over the winter. As a result, Omokanye said there may be an increase in infections over the European summer. This may include severe cases that require hospital treatment. A need for 'continued vigilance': ECDC expert advice SARS-CoV-2 is becoming more endemic in communities but it is "still not a season pathogen, like influenza," said Omokanye. Covid still appears to move and mutate in unpredictable ways and that "stresses the need for continued vigilance and not being complacent about SARS-CoV-2," said Omokanye. "Just in the same way that we're not complacent about influenza or RSV." Bangladesh has already seen deaths due to Covid in June. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 2025 Top Trending local enterprise accounting software [Click Here] Esseps Learn More Undo China and Singapore have also detected new cases of the respiratory disease. Deaths in places like Bangladesh may be partly due to people's poor access to healthcare. By comparison, Omokanye cited Canada, where Nimbus is dominant but without the same rates or severity of cases. But it's not only a case of access to healthcare. "There are multiple factors. First, it's the timing of [a] variant's emergence," Omokanye said. Another, he said, is that there could be a greater possibility for waning immunity where there's been low circulation for a long period of time. With vaccination, there are also several important factors: Which vaccines are available in each country or region and "who they are given to and when," said Omokanye. "The question is: are the vaccines being taken up by that proportion of the population where you see the most severe disease?" Similarly, with healthcare systems and access to supportive treatment, localized differences may determine how seriously infections progress in a population. "They all contribute to the picture of severe disease," said Omokanye. What makes Nimbus different from other Omicron subvariants? ECDC and the world health organization have classified Nimbus as a variant under monitoring (VUM) due to two specific spike mutations. The spikes are the "prongs" that enable the virus to latch onto and infect human cells. They have regularly mutated since SARS-CoV-2 first emerged. Spike protein mutations reduce the ability of human antibodies to neutralize an infection and others that enhance the virus' ability to evade human antibodies. VUM is the lowest category in a system where the more severe stages are Variant of Interest and variant of concern.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store